Valuation: Keros Therapeutics, Inc.

Market Cap 222M 197M 183M 166M 311M 20.94B 316M 2.19B 859M 11B 831M 814M 35.06B P/E 2026 *
-2.02x
P/E 2027 * -1.79x
Enterprise Value 222M 197M 183M 166M 311M 20.94B 316M 2.19B 859M 11B 831M 814M 35.06B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 16.1x
Free-Float
46.49%
Yield 2026 *
-
Yield 2027 * -
1 day-1.93%
1 week-0.45%
Current month-1.93%
1 month-0.09%
3 months+5.37%
6 months-4.12%
Current year-45.09%
1 week 10.63
Extreme 10.63
11.68
1 month 10.63
Extreme 10.63
12.26
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 2015-11-30
Director of Finance/CFO 55 2026-08-02
Chief Tech/Sci/R&D Officer 53 2019-05-31
Director TitleAgeSince
Chairman 70 2024-06-30
Director/Board Member 63 2016-03-31
Director/Board Member 50 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
8/18/26 Sell

Executive/Senior Manager

-3,568 0.0180%
8/18/26 Sell

General Counsel

-4,485 0.0227%
8/18/26 Sell

Chief Financial Officer

-1,224 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
-1.93%-0.45%-26.40%-60.55% 226M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.06%+4.45%+44.10%+104.64% 38.77B
Weighted average by Cap. +0.32%+4.67%+51.24%+127.66%

Financials

2026 *2027 *
Net sales 15.57M 13.86M 12.83M 11.62M 21.87M 1.47B 22.17M 154M 60.33M 772M 58.39M 57.17M 2.46B 13.73M 12.22M 11.31M 10.25M 19.28M 1.3B 19.55M 136M 53.2M 681M 51.49M 50.41M 2.17B
Net income -110M -98.25M -90.97M -82.4M -155M -10.42B -157M -1.09B -428M -5.47B -414M -405M -17.45B -147M -131M -122M -110M -207M -13.92B -210M -1.46B -571M -7.31B -553M -541M -23.31B
Net Debt - -
Projected Income Statement - Annual - Keros Therapeutics, Inc.
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
92
Date Price Change Volume
26-10-21 US$11.18 -1.93% 178,138
26-10-20 US$11.40 +3.07% 153,379
26-10-19 US$11.06 +3.75% 210,647
26-10-16 US$10.66 -3.96% 169,639
26-10-15 US$11.10 +0.45% 96,665
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Keros Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.18USD
Average target price
19.83USD
Spread / Average Target
+77.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Keros Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. KROS Stock